SoylentNews is people
SoylentNews
Researchers have developed a vaccine that may be effective at preventing many forms of the common cold (rhinovirus):
A mixture of 25 types of inactivated rhinovirus can stimulate neutralizing antibodies against all 25 in mice, and a mixture of 50 types can do the same thing in rhesus macaques. In this paper, antibodies generated in response to the vaccine were tested for their ability to prevent the virus from infecting human cells in culture. However, the vaccines were not tested for their ability to stop animals from getting sick.
"There are no good animal models of rhinovirus replication," Moore says. "The next step would be human challenge models with volunteers, which are feasible because the virus is not very pathogenic."
Emory has optioned the vaccine technology to a startup company, Meissa Vaccines, Inc., which is pursuing a product development plan with support from the National Institute of Allergy and Infectious Diseases' vaccine manufacturing services.
A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques (open, DOI: 10.1038/ncomms12838) (DX)
As the predominant aetiological agent of the common cold, human rhinovirus (HRV) is the leading cause of human infectious disease. Early studies showed that a monovalent formalin-inactivated HRV vaccine can be protective, and virus-neutralizing antibodies (nAb) correlated with protection. However, co-circulation of many HRV types discouraged further vaccine efforts. Here, we test the hypothesis that increasing virus input titres in polyvalent inactivated HRV vaccine may result in broad nAb responses. We show that serum nAb against many rhinovirus types can be induced by polyvalent, inactivated HRVs plus alhydrogel (alum) adjuvant. Using formulations up to 25-valent in mice and 50-valent in rhesus macaques, HRV vaccine immunogenicity was related to sufficient quantity of input antigens, and valency was not a major factor for potency or breadth of the response. Thus, we have generated a vaccine capable of inducing nAb responses to numerous and diverse HRV types.
(Score: 2) by Aiwendil on Wednesday September 28 2016, @07:53AM
Let me point out a few things here..
1) flu-vaccines are only 50-80% effective if you are healthy (and less so if you're not)
2) flu-vaccines are strain-specific - the cocktail you get only protects against 3-5 strains out of the 30 or so that emerge every year.
2b) it takes a couple of months (weeks in emergencies) to ramp up production - so they have to gamble on which three strains they need to target before they become pandemic
3) it is different strains constantly - so any shot you got more than nine months ago will not help you against what the lastest unvaccinated schmuck brought home from its travels
4) you will get sick from the vaccine (it is the idea of it; but only weakly so, and only for 2-3 days and (most important) won't be contagious)
5) The people who buys and uses lots of remedies tend to not be helthy to begin with (most "remedies" are excellent at hiding symptoms but don't do squat for the illness (caffeine and amphetamines are great to hide a cold, but you will be the schmuck that infects everyone))
6) unless you have a large enough sample size and follow got protocol in taking data your experiences are worth somewhere between zip and nil when it comes to protecting a population.
6b) also - did the people you know got sick within 2-3 weeks of vaccination? If so they got sick before the vaccine got to have full effect (if they got [noticeable] sick within four days they where already infected before getting the shot)
6c) You are telling me the hospitals in your country shuts down for two weeks every winter? Holy crap ;) (physicians and their nurses tend to have a coverage of about 80% when it comes to the flu-vaccination [in industralised countries])
7) in my country between 45 and 55% of tne people over 65 gets vaccinayed each year, and since they are not dropping like flies (life expectancy is 81.7yrs here) the whole "always get sick" can be ignored.